Trade Names:Xylocaine with Epinephrine- Injection 0.5% with 1:200,000 epinephrine- Injection 1% with 1:100,000 epinephrine- Injection 2% with 1:50,000 epinephrine- Injection 2% with 1:100,000 epinephrine
Trade Names:Xylocaine MPF with Epinephrine- Injection 1% with 1:200,000 epinephrine- Injection 1.5% with 1:200,000 epinephrine- Injection 2% with 1:200,000 epinephrineXylocaine Parenteral with Epinephrine (Canada)
Stabilizes neuronal membranes by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action.Epinephrine
Stimulates both alpha- and beta-receptors within sympathetic nervous system; relaxes smooth muscle of bronchi and iris and is an antagonist of histamine.
Production of local or regional anesthesia by infiltration techniques such as percutaneous injection, by peripheral nerve block techniques such as brachial plexus and intercostals, and by central neural techniques such as lumbar and caudal epidural blocks.
History of hypersensitivity to local anesthetics of the amide type.
Dose determined by number of dermatomes to be anesthetized (2 to 3 mL/dermatome). The dose of local anesthetic administered varies with the procedure, vascularity of the tissues, depth of anesthesia, degree of required muscle relaxation, duration of anesthesia desired, and the physical condition of the patient. Reduce dosages for children, the elderly, debilitated patients, and patients with cardiac or liver disease. Consult individual prescribing information for dosage recommendations.
Store at 59° to 86°F.
May cause severe persistent hypertension or cerebrovascular accidents.MAOIs (eg, isocarboxazid), tricyclic antidepressants (eg, amitriptyline)
Severe prolonged hypertension may occur.Phenothiazines (eg, thioridazine), butyrophenones (droperidol)
May reduce or reverse the pressor effect of epinephrine.
Lidocaine IM injection may increase creatine phosphokinase levels, which may compromise the diagnosis of acute MI.
Bradycardia; hypotension (3%); CV collapse; cardiac arrest.
Excitation; depression; lightheadedness; nervousness; apprehension; euphoria; confusion; dizziness; drowsiness; sensations of heat, cold, or numbness; twitching; tremors, convulsions, unconsciousness; positional headache (3%); shivering (2%).
Tinnitus; blurred or double vision; permanent injury to extraocular muscles.
Vomiting; loss of bowel control.
Loss of bladder control; loss of sexual function.
Respiratory depression or arrest.
Allergy (eg, cutaneous lesions, urticaria, edema, anaphylactoid reactions); backache.
Category B .
Reduce dose; commensurate with age, body weight, and physical condition.
Use with caution in areas of the body supplied by end arteries or having compromised blood supply, patients with neurological disease, spinal deformities, septicemia and severe hypertension, impaired CV function, or hepatic disease.
May exhibit exaggerated vasoconstrictor response and ischemic injury or necrosis may result.
Copyright © 2009 Wolters Kluwer Health.